USPTO 2015–2025 USPTO PatentsView US Corporation

Biomarin Pharmaceutical Inc.

USPTO PatentsView assignee record - 85 granted patents across 18 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Explore the portfolio See the ranking

Total patents granted

CPC technology areas

18.8

Avg claims per patent

-33%

5-year filing velocity

The verdict

Biomarin holds 85 US patents across 18 technology areas, rank #4,183 of 50,000 tracked assignees.

#4,183
of 50,000 US assignees by volume: Top 22%
by Innovation Score (45.8/100): 18.8
avg claims per patent: -33%
filing velocity, last 5 yrs

Portfolio overview

Biomarin Pharmaceutical Inc. has been granted 85 US utility patents between 2015 and 2025, placing Biomarin Pharmaceutical Inc. at rank #4,183 across all assignees tracked by PlainPatent. This portfolio spans 18 distinct Cooperative Patent Classification (CPC) subclasses, averaging 18.8 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a US Corporation, Biomarin Pharmaceutical Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Biomarin sits between Arlanxeo Deutschland Gmbh (85 patents, rank #4,179) and Chemetall Gmbh (85 patents, rank #4,187) - the closest US assignees by grant volume. The composite Innovation Score of 45.8/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 34 grants, compared with 51 in the 2015–2019 window, a -33% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Biomarin Pharmaceutical Inc.'s 18.8 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 18 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Biomarin Pharmaceutical Inc. against peers pursuing similar technology classes.

Arlanxeo Deutschl…

85
Arthrocare

85
Avalara

85
Beijing Jingdong…

85
Boehringer Ingelh…

85
Bitdefender IPR M…

85
Changzhou Univers…

85
Chemetall

85
Biomarin Pharmace… ◀

85

What this shows Biomarin holds 85 patents at rank #4,183, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Biomarin

By rank, the assignees closest to #4,183 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Biomarin's primary technology class.

Biomarin's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

46 Top 22% higher than 78% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Biomarin Pharmaceutical Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	10	11.8%
2016	7	8.2%
2017	12	14.1%
2018	8	9.4%
2019	14	16.5%
2020	9	10.6%
2021	4	4.7%
2022	9	10.6%
2023	5	5.9%
2024	3	3.5%
2025	4	4.7%

Which technologies does Biomarin Pharmaceutical Inc. patent most?

A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 68

A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 56

C12N - MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA 37

C12Y - ENZYMES 29

C07K - PEPTIDES 24

C07D - HETEROCYCLIC COMPOUNDS 22

G01N - INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 20

C12Q - MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES 15

A01K - ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS 5

Y02A - TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE 5

C07H - SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS 3

A61B - DIAGNOSIS; SURGERY; IDENTIFICATION 3

A61M - DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR 3

C07C - ACYCLIC OR CARBOCYCLIC COMPOUNDS 2

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY 2

Top 15 of 18 technology areas

Patent Moat Analysis

Portfolio Volume Light

Tech Breadth Focused

Claim Depth Standard

Velocity Declining

Where it ranks

Overall rank by patents

#4,183

Across all tracked assignees

Innovation Score

45.8 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Biomarin Pharmaceutical Inc. hold?

Biomarin Pharmaceutical Inc. holds 85 US granted patents filed between 2015 and 2025, spanning 18 technology areas.

What is Biomarin Pharmaceutical Inc.'s Innovation Score?

Biomarin Pharmaceutical Inc. has an Innovation Score of 45.8 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Biomarin Pharmaceutical Inc. focus on?

Biomarin Pharmaceutical Inc.'s top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 68 patents. The company has filed patents in 18 CPC subclasses total.

Is Biomarin Pharmaceutical Inc.'s patent filing rate increasing or decreasing?

Biomarin Pharmaceutical Inc.'s recent filing velocity is -33% compared to the prior five-year period. Filing activity has slowed relative to earlier years.

What does claim depth mean for Biomarin Pharmaceutical Inc.'s patents?

Biomarin Pharmaceutical Inc.'s patents average 18.8 claims each. This falls within the standard range, providing solid legal coverage.

How is the Biomarin Pharmaceutical Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Biomarin's 85 grants land it in the top 22% by Innovation Score, but volume alone doesn't tell you where the strength sits.

Read that count against the largest US assignees before treating it as dominance - Biomarin ranks #4,183 of 50,000. Top 50 holders
Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.